1
|
Haq IU, Mehmood Z, Khan GA, Kainat B, Ahmed B, Shah J, Sami A, Nazar MS, Xu J, Xiang H. Modeling the effect of climatic conditions and topography on malaria incidence using Poisson regression: a Retrospective study in Bannu, Khyber Pakhtunkhwa, Pakistan. Front Microbiol 2024; 14:1303087. [PMID: 38287956 PMCID: PMC10822983 DOI: 10.3389/fmicb.2023.1303087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 12/26/2023] [Indexed: 01/31/2024] Open
Abstract
Background Malaria has been identified as a crucial vector-borne disease around the globe. The primary aim of this study was to investigate the incidence of malaria in the district of Bannu and its relationship with climatic conditions such as temperature, rainfall, relative humidity, and topography. Methods Secondary data were obtained from the metrological office and government hospitals across the district for 5 years (2013-2017). A Poisson regression model was applied for the statistical analysis. Results and discussion The number of reported cases of malaria was 175,198. The regression analysis showed that temperature, relative humidity, and rainfall had a significant association (p < 0.05) with malaria incidence. In addition, the topographic variables were significantly associated (p < 0.05) with malaria incidence in the region. The percent variation in the odds ratio of incidence was 4% for every unit increase in temperature and 2% in humidity. In conclusion, this study indicated that the temperature, humidity, rainfall, and topographic variables were significantly associated with the incidence of malaria. Effective malaria control and interventions integrated with climatic factors must be considered to overcome the disease burden.
Collapse
Affiliation(s)
- Ijaz Ul Haq
- Department of Public Health & Nutrition, The University of Haripur, Haripur, Khyber Pakhtunkhwa, Pakistan
| | - Zafar Mehmood
- Department of Maths, Stats & Computer Science, The University of Agriculture Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan
| | - Gausal Azam Khan
- Department of Clinical Nutrition, College of Applied Medical Sciences, King Faisal University, Al Ahsa, Saudi Arabia
| | - Bushra Kainat
- Department of Public Health & Nutrition, The University of Haripur, Haripur, Khyber Pakhtunkhwa, Pakistan
| | - Bilal Ahmed
- School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China
| | - Jahan Shah
- Department of Social Medicine and Health Education, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China
| | - Amtul Sami
- Department of Health Biotechnology, Women University, Swabi, Khyber Pakhtunkhwa, Pakistan
| | - Muhammad Subhan Nazar
- Department of Public Health & Nutrition, The University of Haripur, Haripur, Khyber Pakhtunkhwa, Pakistan
| | - Jielian Xu
- Department of Clinical Nutrition, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
| | - He Xiang
- Department of Clinical Nutrition, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
| |
Collapse
|
2
|
Niazi R, Parveen G, Noman M, Mukhtar N, Hadayat N, Sami A, Khaliq B, Shrestha J, Ullah I. Comparative expression analysis of sucrose phosphate synthase gene family in a low and high sucrose Pakistani sugarcane cultivars. PeerJ 2023; 11:e15832. [PMID: 37719124 PMCID: PMC10503496 DOI: 10.7717/peerj.15832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Accepted: 07/11/2023] [Indexed: 09/19/2023] Open
Abstract
Sugarcane is the world's largest cultivated crop by biomass and is the main source of sugar and biofuel. Sucrose phosphate synthase (SPS) enzymes are directly involved in the synthesis of sucrose. Here, we analyzed and compared one of the important gene families involved in sucrose metabolism in a high and low sucrose sugarcane cultivar. A comprehensive in silico analysis of the SoSPS family displayed their phylogenetic relationship, gene and protein structure, miRNA targets, protein interaction network (PPI), gene ontology and collinearity. This was followed by a spatial expression analysis in two different sugarcane varieties. The phylogenetic reconstruction distributed AtSPS, ZmSPS, OsSPS, SoSPS and SbSPS into three main groups (A, B, C). The regulatory region of SoSPS genes carries ABRE, ARE, G-box, and MYC as the most dominant cis-regulatory elements. The PPI analysis predicted a total of 14 unique proteins interacting with SPS. The predominant expression of SPS in chloroplast clearly indicates that they are the most active in the organelle which is the hub of photosynthesis. Similarly, gene ontology attributed SPS to sucrose phosphate synthase and glucosyl transferase molecular functions, as well as sucrose biosynthetic and disaccharide biological processes. Overall, the expression of SPS in CPF252 (high sucrose variety) was higher in leaf and culm as compared to that of CPF 251 (low sucrose variety). In brief, this study adds to the present literature about sugarcane, sucrose metabolism and role of SPS in sucrose metabolism thereby opening up further avenues of research in crop improvement.
Collapse
Affiliation(s)
- Robi Niazi
- Department of Botany, Women University Swabi, Swabi, Khyber Pakhtun Khwa, Pakistan
| | - Gulnaz Parveen
- Department of Botany, Women University Swabi, Swabi, Khyber Pakhtun Khwa, Pakistan
| | - Muhammad Noman
- National Institute for Genomics and Advanced Biotechnology, National Agricultural Research Center Islamabad Pakistan, Islamabad, Capital, Pakistan
| | - Naila Mukhtar
- Department of Botany, University of Okara, Okara, Punjab, Pakistan
| | - Naila Hadayat
- Department of Botany, Division of Science & Technology, University of Education, Lahor
| | - Amtul Sami
- Health Biotechnology, Women University Swabi, Swabi, Khyber Pakhtun Khwan, Pakistan
| | - Binish Khaliq
- Department of Botany, University of Okara, Okara, Punjab, Pakistan
| | - Jiban Shrestha
- Nepal Agricultural Research Council, National Plant Breeding and Genetics Research Centre, Khumaltar, Lalitpur, Nepal
| | - Irfan Ullah
- Department of Zoology, Karakaram International University, Ghizer, Gilgit, Pakistan
| |
Collapse
|
3
|
Fisher L, Ahmed O, Chalchal H, Deobald R, El-Gayed A, Graham P, Groot G, Haider K, Iqbal N, Johnson K, Le D, Mahmood S, Manna M, Meiers P, Pauls M, Salim M, Sami A, Wright P, Younis M, Ahmed S. P058 Outcomes of Rural Men With Breast Cancer: A Multicenter Population Based Retrospective Cohort Study. Breast 2023. [DOI: 10.1016/s0960-9776(23)00177-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
4
|
Morgan JL, Bromley HL, Dave RV, Masannat Y, Masudi T, Mylvaganam S, Elgammal S, Barnes N, Down S, Holcombe C, Potter S, Gardiner MD, Maxwell AJ, Somasundaram SK, Sami A, Kirwan C, Harvey J. Results of shared learning of a new magnetic seed localisation device - A UK iBRA-NET breast cancer localisation study. Eur J Surg Oncol 2022; 48:2408-2413. [PMID: 36068125 DOI: 10.1016/j.ejso.2022.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 07/11/2022] [Accepted: 07/14/2022] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Shared learning is imperative in the assessment and safe implementation of new healthcare interventions. Magnetic seeds (Magseed®) potentially offer logistical benefit over wire localisation for non-palpable breast lesions but few data exist on outcomes comparing these techniques. A national registration study (iBRA-NET) was conducted to collate device outcomes. In order to share learning, thematic analysis was conducted to ascertain early clinical experiences of Magseed® and wire guided localisation and explore how learning events may be applied to improve clinical outcomes. METHODS A qualitative study of 27 oncoplastic surgeons, radiologists and physicians was conducted in January 2020 to ascertain the feasibility and challenges associated with Magseed® versus wire breast localisation surgery. Four focus groups were asked to discuss experiences, concerns and shared learning outcomes which were tabulated and analysed thematically. RESULTS Three key themes were identified comparing Magseed® and wire localisation of breast lesions relating to preoperative, intraoperative and postoperative learning outcomes. Percutaneous Magseed® detection, instrument interference and potential seed or wire dislodgement were the most common issues identified. Clinician experience suggested Magseed® index lesion identification was non-inferior to wire placement and improved the patient pathway in terms of scheduling and multi-site insertion. CONCLUSIONS Prospective shared learning suggested Magseed® offered additional non-clinical benefits over wire localisation, improving the efficiency of the patient pathway. Recommendations for improving breast localisation technique, appropriate patient selection and clinical practice through shared learning are discussed that may aid other surgeons in the adoption of this relatively new technique.
Collapse
Affiliation(s)
- Jenna L Morgan
- Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, United Kingdom
| | - Hannah L Bromley
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom
| | - Rajiv V Dave
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
| | | | - Tahir Masudi
- Rotherham NHS Foundation Trust, Rotherham, United Kingdom
| | | | - Suzanne Elgammal
- University Hospital Crosshouse, NHS Ayrshire and Arran, United Kingdom
| | - Nicola Barnes
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom
| | - Sue Down
- James Paget University Hospital, Great Yarmouth, United Kingdom
| | - Chris Holcombe
- Breast Unit, Royal Liverpool University Hospital, United Kingdom
| | - Shelley Potter
- National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom; Bristol Breast Care Centre, North Bristol NHS Trust, United Kingdom
| | - Matthew D Gardiner
- Department of Plastic Surgery, Frimley Health NHS Foundation Trust, Slough, United Kingdom; Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
| | - Anthony J Maxwell
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom; Division of Informatics, Imaging & Data Sciences, Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom
| | | | - Amtul Sami
- Lincoln County Hospital, United Lincolnshire Hospitals NHS Trust, United Kingdom
| | - Cliona Kirwan
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
| | - James Harvey
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
| |
Collapse
|
5
|
Khalid S, Calderon-Larranaga S, Sami A, Hawley S, Judge A, Arden N, Van Staa TP, Cooper C, Abrahamsen B, Javaid MK, Prieto-Alhambra D. Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. Osteoporos Int 2022; 33:1579-1589. [PMID: 35138412 DOI: 10.1007/s00198-021-06262-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Accepted: 12/03/2021] [Indexed: 10/19/2022]
Abstract
UNLABELLED The aim of this study was to evaluate the risk of acute myocardial infarction in patients taking osteoporosis medication. Patients were taken from the SIDIAP or CPRD database and were matched using propensity scores. Patients with diabetes and chronic kidney disease taking SERMs were at an increased risk. The results favour the cardiovascular safety of alendronate as a first-line choice for osteoporosis treatment. INTRODUCTION This study aims to evaluate the comparative safety of anti-osteoporosis drugs based on the observed risk of acute myocardial infarction while on treatment in a primary care setting. METHODS This is a propensity-matched cohort study and meta-analysis. This study was conducted in two primary care record databases covering UK NHS (CPRD) and Catalan healthcare (SIDIAP) patients during 1995-2014 and 2006-2014, respectively. The outcome was acute myocardial infarction while on treatment. Users of alendronate (reference group) were compared to those of (1) other oral bisphosphonates (OBP), (2) strontium ranelate (SR), and (3) selective oestrogen receptor modulator (SERM), after matching on baseline characteristics (socio-demographics, fracture risk factors, comorbidities, and concomitant drug use) using propensity scores. Multiple imputation was used to handle missing data on confounders and competing risk modelling for the calculation of relative risk (sub-distribution hazard ratios (SHR)) according to therapy. Country-specific data were analysed individually and meta-analysed. RESULTS A 10% increased risk of acute myocardial infarction was found in users of other bisphosphonates as compared to alendronate users within CPRD. The meta-analysis of CPRD and SIDIAP results showed a 9% increased risk in users of other bisphosphonate as compared to alendronate users. Sensitivity analysis showed SERMS users with diabetes and chronic kidney disease were at an elevated risk. CONCLUSIONS This study provides additional data on the risk of acute myocardial infarction in patients receiving osteoporosis treatment. The results favour the cardiovascular safety of alendronate as a first-line choice for osteoporosis treatment.
Collapse
Affiliation(s)
- S Khalid
- Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.
- Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.
| | - S Calderon-Larranaga
- Family and Community Medicine Teaching Unit of Granada, Cartuja University Health Centre, Andalusian Health Service (SAS), Avda. Juan Pablo II, 18001, Granada, Spain
- Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University of London, London, Turner Street, E1 2AB, UK
| | - A Sami
- Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK
| | - S Hawley
- Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK
- Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK
- Bristol NIHR Biomedical Research Centre, Musculoskeletal Research Unit, University of Bristol, Southmead Hospital, Bristol, BS10 5NB, UK
| | - A Judge
- Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK
- Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK
- Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University of London, London, Turner Street, E1 2AB, UK
- Bristol NIHR Biomedical Research Centre, Musculoskeletal Research Unit, University of Bristol, Southmead Hospital, Bristol, BS10 5NB, UK
| | - N Arden
- Arthritis Research UK Centre for Sport, Exercise, and Osteoarthritis, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK
| | - T P Van Staa
- Centre for Health Informatics, University of Manchester, Vaughan House, Portsmouth Road, Manchester, M13 9PL, UK
- Utrecht Institute for Pharmaceutical Sciences, Utrecht University, David de Wied building, Universiteitsweg 99, 3584 CG, Utrecht, Netherlands
| | - C Cooper
- Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK
- Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK
- NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK
| | - B Abrahamsen
- Odense Patient Data Explorative Network OPEN, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - M Kassim Javaid
- Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK
| | - D Prieto-Alhambra
- Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK
- GREMPAL (Grup de Recerca en Malalties Prevalents de L'Aparell Locomotor) Research Group, CIBERFes and Idiap Jordi Gol Primary Care Research Institute, Universitat Autònoma de Barcelona and Instituto de Salud Carlos III, Gran Via de Les Corts Catalanes, 591 Atico, 08007, Barcelona, Spain
| |
Collapse
|
6
|
Herskind C, Sami A, MacKay A. OC-0099 Differentially expressed genes and pathways in normal skin fibroblasts after irradiation in vitro. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02475-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Dave RV, Barrett E, Morgan J, Chandarana M, Elgammal S, Barnes N, Sami A, Masudi T, Down S, Holcombe C, Potter S, Somasundaram SK, Gardiner M, Mylvaganam S, Maxwell A, Harvey J. Wire- and magnetic-seed-guided localization of impalpable breast lesions: iBRA-NET localisation study. Br J Surg 2022; 109:274-282. [PMID: 35089321 PMCID: PMC10364683 DOI: 10.1093/bjs/znab443] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Revised: 08/24/2021] [Accepted: 12/03/2021] [Indexed: 08/02/2023]
Abstract
BACKGROUND Wire localization is historically the most common method for guiding excision of non-palpable breast lesions, but there are limitations to the technique. Newer technologies such as magnetic seeds may allow some of these challenges to be overcome. The aim was to compare safety and effectiveness of wire and magnetic seed localization techniques. METHODS Women undergoing standard wire or magnetic seed localization for non-palpable lesions between August 2018 and August 2020 were recruited prospectively to this IDEAL stage 2a/2b platform cohort study. The primary outcome was effectiveness defined as accurate localization and removal of the index lesion. Secondary endpoints included safety, specimen weight and reoperation rate for positive margins. RESULTS Data were accrued from 2300 patients in 35 units; 2116 having unifocal, unilateral breast lesion localization. Identification of the index lesion in magnetic-seed-guided (946 patients) and wire-guided excisions (1170 patients) was 99.8 versus 99.1 per cent (P = 0.048). There was no difference in overall complication rate. For a subset of patients having a single lumpectomy only for lesions less than 50 mm (1746 patients), there was no difference in median closest margin (2 mm versus 2 mm, P = 0.342), re-excision rate (12 versus 13 per cent, P = 0.574) and specimen weight in relation to lesion size (0.15 g/mm2versus 0.138 g/mm2, P = 0.453). CONCLUSION Magnetic seed localization demonstrated similar safety and effectiveness to those of wire localization. This study has established a robust platform for the comparative evaluation of new localization devices.
Collapse
Affiliation(s)
- Rajiv V. Dave
- The Nightingale Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
| | - Emma Barrett
- Department of Medical Statistics, Manchester University Hospitals NHS Foundation Trust, Wythenshawe Hospital, Manchester, UK
| | - Jenna Morgan
- Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK
| | - Mihir Chandarana
- Breast Unit, Lincoln County Hospital, United Lincolnshire Hospitals NHS Trust, Lincoln, UK
| | - Suzanne Elgammal
- Breast Unit, University Hospital Crosshouse, NHS Ayrshire and Arran, Kilmarnock, UK
| | - Nicola Barnes
- The Nightingale Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
| | - Amtul Sami
- Breast Unit, Lincoln County Hospital, United Lincolnshire Hospitals NHS Trust, Lincoln, UK
| | - Tahir Masudi
- Breast screening and assessment unit, Rotherham General Hospital, Rotherham NHS Foundation Trust, Rotherham, UK
| | - Sue Down
- Breast Unit, James Paget University Hospital, Great Yarmouth, UK
| | - Chris Holcombe
- Breast Unit, Liverpool University Hospitals Foundation Trust, Liverpool, UK
| | - Shelley Potter
- National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
- Bristol Breast Care Centre, North Bristol NHS Trust, Bristol, UK
| | | | - Matthew Gardiner
- Department of Plastic Surgery, Frimley Health NHS Foundation Trust, Slough, UK
- Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
| | - Senthurun Mylvaganam
- Health Education West Midlands, Royal Wolverhampton NHS Trust, Wolverhampton, UK
| | - Anthony Maxwell
- The Nightingale Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
- Division of Informatics, Imaging & Data Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - James Harvey
- Correspondence to: Consultant Oncoplastic Breast Surgeon, The Nightingale Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester M23 9LT, UK (e-mail: )
| | | |
Collapse
|
8
|
Abbas K, Sami A, Batool U, Shaikh U. Role of Moderate Risk Suseptibilty Genes in Development of Breast Cancer. JPRI 2022. [DOI: 10.9734/jpri/2022/v34i15b35696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Breast cancer is the most common cause of mortality in females globally and affects the lives of millions of women. It is a leading cause of mortality worldwide, but the dynamics have been changed because of advanced screening and treatment protocols [1]. In the United States, breast cancer has been ranked second most common cause of cancer-related death in women, with the most common being lung cancer [2]. To improve cancer screening, a personalized approach has been discussed, but its implication over large populations can be difficult and require expertise. Early detection leads to a good prognosis whereas the late diagnosis of breast cancer is a challenge for both patient and doctor [3]. Breast cancer became the most prevalently diagnosed cancer worldwide as of 2021 accounting for 12% of new annual cases worldwide, according to the World Health Organization. In2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. Multigene panel testing has identified various genes predisposed to breast cancer development. These genes have different penetrance abilities. BRCA1 and BRCA2 genes are the best known high penetrance gene of hereditary breast cancer. Their discovery has revolutionized the effect in cancer assessment. Tumors from BRCA1 and BRCA2 show distinctive clinicopathological characteristics as compared with other genes causing tumors. Beyond BRCA1 and BRCA2, advances in molecular technique have led to the identification of other genes associated with breast cancer. Some other the high penetrance genes are TP53, PTEN, STK11, and CDH1. Besides high pentrance gene, moderate to low penetrance genes are also recognized as a cancer predisposing genes: PALB, BRIP1, ATM, CHEK2, BARD1, NBN, NF1, RAD51C, RAD51D. Along with risk of breast cancer development these genes also predispose to other malignancies, as well as some genetic disorders.
Collapse
|
9
|
Chalchal HI, Zhu T, Woitas C, Ahmed S, Souied O, Iqbal M, Ahmed O, Sami A, Dueck D, Magdi A. P14.76 Bevacizumab (BEV) alone or in combination with chemotherapy in recurrent Glioblastoma Multiforme (GBM): A real world experience. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Patients with glioblastoma multiforme (GBM) have a median survival of about 14 months. In recurrent GBM no active intervention has shown improvement in survival. Clinical trials has shown that bevacizumab (BEV) alone or in combination with chemotherapy is associated with better progression free survival (PFS). The current study aims to assess efficacy of BEV in real-world setting.
MATERIAL AND METHODS
Population-based retrospective cohort study patients with recurrent GBM diagnosed in the province of Saskatchewan during 2008–2018 and received BEV alone or in combination with chemotherapy were evaluated. Survival was compared with historic control.
RESULTS
43 eligible patients with GBM treated with BEV with or without chemotherapy. 25 patients were treated with Bev alone and 18 patients treated with chemotherapy+ BEV. Median age of the patients were noted to be 53 years. 28 male, and 15 female. 80% of patients treated with single agent BEV had a performance status of either 2 or 3 compared to 33% of patient treated with BEV+ chemotherapy.
Median PFS was 4.6 months with 95% CI 2.9–6.9. Median Overall survival (OS) from the time of diagnosis was 17.5 month. Median OS from the time of start of BEV was 5.4 months with 95% CI 3.4–6.8. Partial response (PR) was noted in 3 patients (7%) with stable disease (SD) in 6 patients (14%). 33 (77%) had progressive disease (PD). We were unable to confirm response status in one patient (2%). No statistically significant difference in response rate for patients treated with BEV and BEV+ Chemotherapy. From the start of Bev to the best response, 11 patients (30.56%) noted decrease in the dose of steroids, 14 patients (38.89%) dose remained unchanged. 7 patients (19.44%) required increase in the dose of steroids. 4 patients (11.11%) were not on steroids. For 7 patients we did not have the information on use of steroids. PFS was better for patients treated with chemotherapy + BEV with median PFS of 6.9 months, 95% CI 3.2- 22.3 verses BEV alone with median PFS 3.53 months 95% CI 1.4–5.3, P-value 0.0449. The Cox regression model for PFS to test comparing Bev with chemotherapy vs. Bev alone with the co-variables of sex, age, and ECOG performance status (PS). The model showed that patient with higher ECOG PS were noted to have inferior PFS with a Hazard ratio of 1.92 95% CI 1.09–3.37. P value of 0.2. Patient treated with BEV+ chemo had better PFS with a HR of 6.44 95% CI 1.86–22.28. P value of 0.003.
CONCLUSION
Retrospective real world study confirms that, patients with recurrent GBM, treatment with BEV is associated with similar PFS as reported in literature. Our study showed similar overall survival from the diagnosis compared to historic control. However the Median OS from Start of BEV was noted to be inferior to what is reported in EORTC EH1.3. Better ECOG performance status is associated with better PFS. Higher number of patients with ECOG 2 and 3 received BEV alone.
Collapse
Affiliation(s)
| | - T Zhu
- Saskatchewan Cancer agency, Saskatoon, SK, Canada
| | - C Woitas
- Allan Blair Cancer Centre, Regina, SK, Canada
| | - S Ahmed
- Saskatoon Cancer Centre, Saskatoon, SK, Canada
| | - O Souied
- Allan Blair Cancer Centre, Regina, SK, Canada
| | - M Iqbal
- Allan Blair Cancer Centre, Regina, SK, Canada
| | - O Ahmed
- Saskatoon Cancer Centre, Saskatoon, SK, Canada
| | - A Sami
- Saskatoon Cancer Centre, Saskatoon, SK, Canada
| | - D Dueck
- Saskatoon Cancer Centre, Saskatoon, SK, Canada
| | - A Magdi
- Allan Blair Cancer Centre, Regina, SK, Canada
| |
Collapse
|
10
|
Dave R, Elgammal S, Barrett E, Barnes N, Sami A, Masudi T, Down S, Holcombe C, Potter S, Somasundaram SK, Gardiner MD, Maxwell AJ, Mylvaganam S, Harvey J. 07. The iBRANET localisation study; A National cohort study of wire-guided and Magseed-guided localisation for impalpable breast lesions. Eur J Surg Oncol 2021. [DOI: 10.1016/j.ejso.2021.03.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
11
|
Hendry J, Ali S, Ahmed O, Chalchal H, El-Gayed A, Haider K, Iqbal N, Johnson K, Le D, Maas B, Manna M, Pauls M, Salim M, Sami A, Wright P, Younis M, Ahmed S. 59P Outcomes of women HER2 positive T1a/bN0M0 breast cancer treated with adjuvant trastuzumab: A retrospective population-based cohort study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
12
|
Bromley HL, Dave R, Holcombe C, Potter S, Maxwell AJ, Kirwan C, Mylvaganam S, Elgammal S, Morgan J, Down S, Masudi T, Sami A, Barnes N, Harvey J. A Novel Mixed-Methods Platform Study Protocol for Investigating New Surgical Devices, with Embedded Shared Learning: Ibra-net Breast Lesion Localisation Study. Int J Surg Protoc 2021; 25:26-33. [PMID: 34013142 PMCID: PMC8114848 DOI: 10.29337/ijsp.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Introduction: New medical devices must have adequate research, such that outcomes are known, enabling patients to be consented with knowledge of the safety and efficacy of the device to be implanted. Device trials are challenging due to the learning curve and iterative assessment of best practice. This study is designed to pilot a national collaborative approach to medical device introduction by breast surgeons in the UK, using breast localisation devices as an exemplar. The aim is to develop an effective and transferable surgical device platform protocol design, with embedded shared learning. Methods and analysis: The iBRA-net localisation study is a UK based prospective, multi-centre platform study, comparing the safety and efficacy of novel localisation devices with wire-guided breast lesion localisation for wide local excision, using Magseed® as the pilot intervention group. Centres performing breast lesion localisation for wide local excision or excision biopsy will be eligible to participate if using one of the included devices. Further intervention arms will be added as new devices are CE marked. Outcomes will be collected via an online database. The primary outcome measure will be identification of the index lesion. Participating surgeons will be asked to record shared learning events via online questionnaires and focus group interviews to inform future study arms. Ethics and dissemination: The study will aim to collect data on 950 procedures for each intervention (Magseed® and wire localisation) from UK breast centres over an 18-month period. Shared learning will be prospectively evaluated via thematic analysis to refine breast localisation technique and to promote early identification of potential pitfalls and problems. Results will be presented at national and international conferences and published in peer reviewed journals. Registration: This is a UK national audit registered with Manchester University NHS Foundation Trust. Highlights
Collapse
Affiliation(s)
- Hannah L Bromley
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom.,Health Economics Unit, University of Birmingham, United Kingdom
| | - Rajiv Dave
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom
| | - Chris Holcombe
- Breast Unit, Royal Liverpool University Hospital, United Kingdom
| | - Shelley Potter
- National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.,Bristol Breast Care Centre, North Bristol NHS Trust, United Kingdom
| | - Anthony J Maxwell
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom.,Division of Informatics, Imaging & Data Sciences, Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom
| | - Cliona Kirwan
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom.,Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom
| | | | - Suzanne Elgammal
- University Hospital Crosshouse, NHS Ayrshire and Arran, United Kingdom
| | - Jenna Morgan
- Department of Oncology and Metabolism, University of Sheffield, United Kingdom
| | - Sue Down
- James Paget University Hospital, Great Yarmouth, United Kingdom
| | - Tahir Masudi
- Rotherham NHS Foundation Trust, Rotherham, United Kingdom
| | - Amtul Sami
- Lincoln County Hospital, United Lincolnshire Hospitals NHS Trust, United Kingdom
| | - Nicola Barnes
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom
| | - James Harvey
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, United Kingdom.,Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom
| |
Collapse
|
13
|
Andrahennadi S, Sami A, Haider K, Chalchal H, Le D, Iqbal N, Ahmed O, Salim M, Manna M, Elgayed A, Wright P, Johnson K, Ahmed S. Efficacy of fulvestrant in hormone refractory metastatic breast cancer (mBC): a Canadian province experience. Breast 2021. [DOI: 10.1016/s0960-9776(21)00144-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
14
|
Gheith O, Alotaibi T, Aboatteya H, Nagib A, Halim M, Said T, Abdelhameed M, Elserwy N, Sami A, Nair P. Impact of inhibition of PCSK-9 among renal transplant recipients with high cardiovascular risk. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Steenbergen DJ, Neihapi PT, Koran D, Sami A, Malverus V, Ephraim R, Andrew N. COVID-19 restrictions amidst cyclones and volcanoes: A rapid assessment of early impacts on livelihoods and food security in coastal communities in Vanuatu. Mar Policy 2020; 121:104199. [PMID: 32952270 PMCID: PMC7487203 DOI: 10.1016/j.marpol.2020.104199] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 08/23/2020] [Accepted: 08/24/2020] [Indexed: 05/08/2023]
Abstract
Coastal communities in regions like the Pacific have been impacted by COVID-19 related public health measures that limit the movement of people, trade and access to resources. In disaster-prone countries, like Vanuatu, such measures add to existing pressures on coastal communities' adaptive capacity. To understand how coastal communities in Vanuatu were impacted in the immediate period after COVID-19 measures were placed, and how people responded to the changing circumstances, a rapid appraisal survey was carried out following a nationally declared state of emergency in March 2020. Results reveal changes in village population, loss of cash income, difficulties in accessing food and shifting pressures on particular resources and habitats. The findings provide insights into the ways local adaptive capacity to satisfy livelihood and food security needs differed among rural contexts. From this we argue that broad quantitative impact assessments are important in guiding strategic and longer term responses and adaptations, but that these are made more useful when complemented with qualitative insights on people and place in the short-term.
Collapse
Affiliation(s)
- D J Steenbergen
- Australian National Centre for Ocean, Resources and Security (ANCORS), University of Wollongong, Wollongong, Australia
| | - P T Neihapi
- Vanuatu Fisheries Department (VFD), Port Vila, Vanuatu
- The Pacific Community (SPC), Noumea, New Caledonia
| | - D Koran
- Vanuatu Fisheries Department (VFD), Port Vila, Vanuatu
| | - A Sami
- Vanuatu Fisheries Department (VFD), Port Vila, Vanuatu
| | - V Malverus
- Vanuatu Fisheries Department (VFD), Port Vila, Vanuatu
| | - R Ephraim
- Vanuatu Fisheries Department (VFD), Port Vila, Vanuatu
| | - N Andrew
- Australian National Centre for Ocean, Resources and Security (ANCORS), University of Wollongong, Wollongong, Australia
| |
Collapse
|
16
|
Herskind C, Sticht C, Sami A, Giordano F, Wenz F. Gene Expression Profiles of Fibroblasts Irradiated with Two Protocols in vitro. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
17
|
Lucatelli P, Iezzi R, De Rubeis G, Goldberg SN, Bilbao JI, Sami A, Akhan O, Giuliante F, Pompili M, Tagliaferri L, Valentini V, Gasbarrini A, Colosimo C, Bezzi M, Manfredi R. Immuno-oncology and interventional oncology: a winning combination. The latest scientific evidence. Eur Rev Med Pharmacol Sci 2020; 23:5343-5350. [PMID: 31298386 DOI: 10.26355/eurrev_201906_18201] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Interventional oncology (IO) is an emergent field in interventional radiology that can be considered the fourth pillar of oncology. Interventional oncology has the unique capability to treat malignancy in a loco-regional fashion enabling curative (percutaneous ablation), disease stabilization (intra-arterial chemo/radioembolization), and palliative treatment (such as biliary drainage or nephrostomy). The whole arsenal of IO acts by inducing necrosis and apoptosis, with interactions with the tumour's microenvironment potentially crucial for oncological outcomes. Considering that tumour's microenvironment is a pivotal target for both immuno-oncology and interventional-oncology, the interactions between these two anti-tumour weapons must be investigated to understand their synergy. Interestingly, substantial efforts have been directed to understand which technique combinations are best for specific tumours. This review article summarizes the latest scientific evidence highlighting the future prospective of this winning combination, integrating evidence-reported literature and experience-based perceptions.
Collapse
Affiliation(s)
- P Lucatelli
- Department of Radiological, Oncological and Anatomopathological Sciences, Interventional and Vascular Division, "Sapienza" University of Rome, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Javaid MK, Sami A, Lems W, Mitchell P, Thomas T, Singer A, Speerin R, Fujita M, Pierroz DD, Akesson K, Halbout P, Ferrari S, Cooper C. A patient-level key performance indicator set to measure the effectiveness of fracture liaison services and guide quality improvement: a position paper of the IOF Capture the Fracture Working Group, National Osteoporosis Foundation and Fragility Fracture Network. Osteoporos Int 2020; 31:1193-1204. [PMID: 32266437 PMCID: PMC7280347 DOI: 10.1007/s00198-020-05377-1] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 03/03/2020] [Indexed: 12/23/2022]
Abstract
The International Osteoporosis Foundation (IOF) Capture the Fracture® Campaign with the Fragility Fracture Network (FFN) and National Osteoporosis Foundation (NOF) has developed eleven patient-level key performance indicators (KPIs) for fracture liaison services (FLSs) to guide quality improvement. INTRODUCTION Fracture Liaison Services (FLSs) are recommended worldwide to reduce fracture risk after a sentinel fracture. Given not every FLS is automatically effective, the IOF Capture the Fracture working group has developed and implemented the Best Practice Framework to assess the organisational components of an FLS. We have now developed a complimentary KPI set that extends this assessment of performance to the patient level. METHODS The Capture the Fracture working group in collaboration with the Fragility Fracture Network Secondary Fragility Fracture Special Interest Group and National Osteoporosis Foundation adapted existing metrics from the UK-based Fracture Liaison Service Database Audit to develop a patient-level KPI set for FLSs. RESULTS Eleven KPIs were selected. The proportion of patients: with non-spinal fractures; with spine fractures (detected clinically and radiologically); assessed for fracture risk within 12 weeks of sentinel fracture; having DXA assessment within 12 weeks of sentinel fracture; having falls risk assessment; recommended anti-osteoporosis medication; commenced of strength and balance exercise intervention within 16 weeks of sentinel fracture; monitored within 16 weeks of sentinel fracture; started anti-osteoporosis medication within 16 weeks of sentinel fracture; prescribed anti-osteoporosis medication 52 weeks after sentinel fracture. The final KPI measures data completeness for each of the other KPIs. For these indicators, levels of achievement were set at the < 50%, 50-80% and > 80% levels except for treatment recommendation where a level of 50% was used. CONCLUSION This KPI set compliments the existing Best Practice Framework to support FLSs to examine their own performance using patient-level data. By using this KPI set for local quality improvement cycles, FLSs will be able to efficiently realise the full potential of secondary fracture prevention and improved clinical outcomes for their local populations.
Collapse
Affiliation(s)
- M K Javaid
- The Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Orthopaedic Sciences, University of Oxford, Oxford, OX4 7LD, UK.
| | - A Sami
- The Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Orthopaedic Sciences, University of Oxford, Oxford, OX4 7LD, UK
| | - W Lems
- VU University Medical Center, Amsterdam, The Netherlands
| | - P Mitchell
- The Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Orthopaedic Sciences, University of Oxford, Oxford, OX4 7LD, UK
- School of Medicine, Sydney Campus, The University of Notre Dame Australia, 140 Broadway, Sydney, NSW, 2007, Australia
| | - T Thomas
- Department of Rheumatology, Hôpital Nord, CHU de Saint-Etienne, and INSERM U1059, University of Lyon, Saint-Etienne, France
| | - A Singer
- Department of Medicine, MedStar Georgetown University Hospital and Georgetown University Medical Center, Washington, DC, USA
- Department of Obstetrics and Gynecology, MedStar Georgetown University Hospital and Georgetown University Medical Center, Washington, DC, USA
| | - R Speerin
- Fragility Fracture Network, Zürich, Switzerland
- Musculoskeletal Network, NSW Agency for Clinical Innovation, Chatswood, Australia
| | - M Fujita
- International Osteoporosis Foundation, Nyon, Switzerland
| | - D D Pierroz
- International Osteoporosis Foundation, Nyon, Switzerland
| | - K Akesson
- Department of Orthopaedics, Skane University Hospital, Malmö, Sweden
| | - P Halbout
- International Osteoporosis Foundation, Nyon, Switzerland
| | - S Ferrari
- Division of Bone Disease, Department of Internal Medicine Specialties, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland
| | - C Cooper
- The Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Orthopaedic Sciences, University of Oxford, Oxford, OX4 7LD, UK
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
| |
Collapse
|
19
|
Sami A, Shah FA, Abdullah M, Zhou X, Yan Y, Zhu Z, Zhou K. Melatonin mitigates cadmium and aluminium toxicity through modulation of antioxidant potential in Brassica napus L. Plant Biol (Stuttg) 2020; 22:679-690. [PMID: 32003103 DOI: 10.1111/plb.13093] [Citation(s) in RCA: 45] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2019] [Accepted: 01/21/2020] [Indexed: 05/03/2023]
Abstract
Melatonin has emerged as an essential molecule in plants, due to its role in defence against metal toxicity. Aluminium (Al) and cadmium (Cd) toxicity inhibit rapeseed seedling growth. In this study, we applied different doses of melatonin (50 and 100 µm) to alleviate Al (25 µm) and Cd (25 µm) stress in rapeseed seedlings. Results show that Al and Cd caused toxicity in rapeseed seedling, as evidenced by a decrease in height, biomass and antioxidant enzyme activity. Melatonin increased the expression of melatonin biosynthesis-related Brassica napus genes for caffeic acid O-methyl transferase (BnCOMT) under Al and Cd stress. The genes BnCOMT-1, BnCOMT-5 and BnCOMT-8 showed up-regulated expression, while BnCOMT-4 and BnCOMT-6 were down-regulated during incubation in water. Melatonin application increased the germination rate, shoot length, root length, fresh and dry weight of seedlings. Melatonin supplementation under Al and Cd stress increased superoxide dismutase, catalase, peroxidase, ascorbate peroxidase, proline, chlorophyll and anthocyanin content, as well as photosynthesis rate. Both Cd and Al treatments significantly increased hydrogen peroxide and malondialdehyde levels in rapeseed seedlings, which were strictly counterbalanced by melatonin. Analysis of Cd and Al in different subcellular compartments showed that melatonin enhanced cell wall and soluble fractions, but reduced the vacuolar and organelle fractions in Al- and Cd-treated seedlings. These results suggest that melatonin-induced improvements in antioxidant potential, biomass, photosynthesis rate and successive Cd and Al sequestration play a pivotal role in plant tolerance to Al and Cd stress. This mechanism may have potential implications in safe food production.
Collapse
Affiliation(s)
- A Sami
- College of Agronomy, Anhui Agricultural University, Hefei, China
| | - F A Shah
- Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China
| | - M Abdullah
- School of Life Sciences, Anhui Agricultural University, Hefei, China
| | - X Zhou
- College of Agronomy, Anhui Agricultural University, Hefei, China
| | - Y Yan
- College of Agronomy, Anhui Agricultural University, Hefei, China
| | - Z Zhu
- College of Agronomy, Anhui Agricultural University, Hefei, China
| | - K Zhou
- College of Agronomy, Anhui Agricultural University, Hefei, China
| |
Collapse
|
20
|
Somasundaram S, Potter S, Elgammal S, Maxwell A, Sami A, Dave R, Down S, Barnes N, Harvey J. 14. IMPALPABLE BREAST LESION LOCALISATION, A LOGISTICAL CHALLENGE: RESULTS OF THE UK IBRA-NET NATIONAL PRACTICE QUESTIONNAIRE. Eur J Surg Oncol 2020. [DOI: 10.1016/j.ejso.2020.03.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
21
|
Berencsi K, Sami A, Ali MS, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Van der Lei J, Lapi F, Simonetti M, Reyes C, Sturkenboom MCJM, Prieto-Alhambra D. Correction to: Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int 2020; 31:799. [PMID: 32025756 DOI: 10.1007/s00198-020-05314-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The original version of this article, published on 26 November 2019 contained a mistake.
Collapse
Affiliation(s)
- K Berencsi
- Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
| | - A Sami
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
| | - M S Ali
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
- Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
| | - K Marinier
- Department of Pharmacoepidemiology, Servier, Suresnes, France
| | - N Deltour
- Department of Pharmacoepidemiology, Servier, Suresnes, France
| | | | - L Pedersen
- Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
| | - P Rijnbeek
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - J Van der Lei
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - F Lapi
- Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy
| | - M Simonetti
- Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy
| | - C Reyes
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain
| | | | - D Prieto-Alhambra
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain.
- Botnar Research Centre, Oxford, UK.
| |
Collapse
|
22
|
Berencsi K, Sami A, Ali MS, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Van der Lei J, Lapi F, Simonetti M, Reyes C, Sturkenboom MCJM, Prieto-Alhambra D. Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int 2020; 31:721-755. [PMID: 31696274 DOI: 10.1007/s00198-019-05181-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Accepted: 09/26/2019] [Indexed: 10/25/2022]
Abstract
INTRODUCTION In May 2013 and March 2014, the European Medicines Agency (EMA) issued two decisions restricting the use of strontium ranelate (SR). These risk minimisation measures (RMM) introduced new contraindications and limited the indications of SR therapy. The EMA required an assessment of the impact of RMMs on the use of SR in Europe. Methods design: multi-national, multi-database cohort Setting: electronic medical record databases based on hospital (Denmark) and primary care provenance (Italy, Spain, the Netherlands, UK). PARTICIPANTS the database source populations were included for population-based analyses, and SR users for patient-level analyses. INTERVENTION New RMMs included contraindications (ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, uncontrolled hypertension) and restricted SR indication to severe osteoporosis with initiation by experienced physician and not as first line anti-osteoporosis therapy. METHODS Prevalence and incidence rates of SR use in the population; prevalence of contraindications and restricted indications in SR users, plus 1-year therapy persistence. Drug use measures were calculated in three periods for comparison: reference (2004 to May 2013), transition (June 2013 to March 2014) and assessment (from April 2014 to end 2016). RESULTS The study population included 143 million person-years(PY) of follow-up and 76,141 incident episodes of SR treatment. Average monthly prevalence rates of SR use dropped by 86.4% from 62.6/10,000 PY (95 CI 62.4-62.9) in the reference to 8.5 (8.5-8.6) in the assessment period. Similarly, the incidence rate of SR use fell by 97.3% from 7.4/10,000 PY (7.4-7.4) to 0.2 (0.2-0.2) between the reference and assessment period. The prevalence of any contraindication decreased, whilst the prevalence of restricted indications increased in these periods. One-year persistence decreased in the assessment compared with reference period. CONCLUSIONS Our study demonstrates a substantial impact of the regulatory action to restrict use of SR in Europe: SR utilisation overall decreased strongly. The proportion of patients fulfilling the restricted indications, without contraindications, increased after the proposed RMMs.
Collapse
Affiliation(s)
- K Berencsi
- Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
| | - A Sami
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
| | - M S Ali
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
- Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
| | - K Marinier
- Department of Pharmacoepidemiology, Servier, Suresnes, France
| | - N Deltour
- Department of Pharmacoepidemiology, Servier, Suresnes, France
| | | | - L Pedersen
- Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
| | - P Rijnbeek
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - J Van der Lei
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - F Lapi
- Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy
| | - M Simonetti
- Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy
| | - C Reyes
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain
| | | | - D Prieto-Alhambra
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain.
- Botnar Research Centre, Windmill Road, Oxford, OX37LD, UK.
| |
Collapse
|
23
|
Malagari K, Iezzi R, Goldberg SN, Bilbao JI, Sami A, Akhan O, Giuliante F, Pompili M, Crocetti L, Valentini V, Gasbarrini A, Colosimo C, Manfredi R. The ten commandments of chemoembolization: expert discussion and report from Mediterranean Interventional Oncology (MIOLive) congress 2017. Eur Rev Med Pharmacol Sci 2019; 22:372-381. [PMID: 29424893 DOI: 10.26355/eurrev_201801_14184] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. The mechanism of action of c-TACE is the induction of tumor necrosis due to the high concentration of the chemotherapeutic that is delivered only locally and to the embolic effect that causes ischemia and increased dwell time of the chemotherapeutic in the tumor. Recently, DEB-TACE has emerged as a variation of c-TACE with the potential for the selective delivery of large amounts of drugs to the tumor for a prolonged period, thereby decreasing plasma levels of the chemotherapeutic agent and related systemic effects. There is an increasing consensus that compared with conventional lipiodol-based regimen, DEB-TACE offers standardized methodology, is more reproducible and is associated with improved response and significantly better safety profile. Using an easy to access point by point format, this manuscript summarizes the expert discussion from the Mediterranean Interventional Oncology Live Congress (MIOLive 2017) about the role of TACE in the treatment of liver tumors.
Collapse
Affiliation(s)
- K Malagari
- 2nd and 1st Department of Radiology, National and Kapodistrian University of Athens, Medical School, Evgenidion Hospital, Athens, Greece.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Ahmed S, Chalchal H, Dwernychuk L, Iqbal N, Salim M, Gowan-Moody D, Asif T, Khan M, Lim J, Bulych D, Ahmed O, Sami A, Kontulainen S, Leis A. Role of individualized intervention(s) on quality of life (QoL) and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer (bc): MyChoice study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
25
|
Elimairi I, Elimairi A, Sami A, Salah A. The use of calcitonin, denosumab and corticosteroid therapy in the management of bone pathological state (BPS). Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Elimairi I, Sami A, Salah A. Kimuras disease (KD): a new gender and continent. Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Elimairi I, Sami A, Salah A, Yousif B. Cell block: a correlation of diagnostic accuracy in salivary gland tumors. Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
28
|
Crocetti L, Iezzi R, Goldberg SN, Bilbao JI, Sami A, Akhan O, Giuliante F, Pompili M, Malagari K, Valentini V, Gasbarrini A, Colosimo C, Manfred R. The ten commandments of liver ablation: expert discussion and report from Mediterranean Interventional Oncology (MIOLive) congress 2017. Eur Rev Med Pharmacol Sci 2018; 22:3896-3904. [PMID: 29949165 DOI: 10.26355/eurrev_201806_15274] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Percutaneous liver ablation has become a cornerstone of the recently developed subspecialty of radiology - that is, interventional oncology. Thermal ablation technology has evolved rapidly during the past decades, with substantial technical and procedural improvements that can help obtain better clinical outcomes and safety profiles. Due to the widespread use of percutaneous ablation, a comprehensive review of the methodologic and technical considerations seems to be mandatory. This article summarizes the expert discussion and report from Mediterranean Interventional Oncology Live Congress (MIOLive 2017) that was held in Rome, Italy, integrating evidence-reported literature and experience-based perceptions, to assist not only residents and fellows who are training in interventional radiology but also practicing colleagues who are approaching to this locoregional treatment.
Collapse
Affiliation(s)
- L Crocetti
- Division of Interventional Radiology, Department of Diagnostic and Interventional Radiology and Nuclear Medicine, Cisanello University Hospital, Pisa, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Abdelmaksoud M, Abuelsalheen O, Ibrahim K, AbdelRazek M, Abdelfattah A, Abdelaziz A, Darwish A, Hassanien M, Ismail A, Hosny A, Hazem A, Sami A, Fattah Y, Sze D. 3:09 PM Abstract No. 122 Lobar or whole-liver Yttrium-90 radioembolization using resin microspheres without prophylactic embolization of the gastroduodenal artery. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
30
|
Seifi F, Clark M, Sami A, Azodi M. Recurrent Endometrial Cancer : Robotic-Assisted Laparoscopy, Debulking of Tumor with Dense Adhesion to Iliac Vessels, Involving Upper Vagina and Ureterovesical Junction. J Minim Invasive Gynecol 2017. [DOI: 10.1016/j.jmig.2017.08.547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Siddiqui H, Tasneem S, Farooq S, Sami A, Rahman AU, Choudhary MI. Harmaline and its Derivatives Against the Infectious Multi-Drug Resistant Escherichia coli. Med Chem 2017; 13:465-476. [PMID: 28124613 DOI: 10.2174/1573406413666170125113832] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Revised: 01/21/2017] [Accepted: 01/21/2017] [Indexed: 11/22/2022]
Abstract
BACKGROUND Multidrug resistance (MDR) is a major challenge in the treatment of infectious diseases. The MDR in urinary tract infection causing bacteria, such as Escherichia coli, has made treatment of UTI very difficult. OBJECTIVE The aims of the current study were to synthesize a library of harmaline derivatives, and to evaluate their activity against various strains of multi-drug resistance (MDR) E. coli. METHOD Harmaline derivatives were synthesized by the reaction of harmaline (1) with various acid halides and anhydrides. These compounds were subjected to susceptibility determination by in vitro MTT assay. The changes in morphology of the bacterial cells after the treatment with harmaline (1) and its new derivatives 2 and 3 were studied through scanning electron, atomic force and fluorescence microscopy. Effect of harmaline and its derivatives on the production of Reactive Oxygen Species (ROS) in MDR E. coli was assessed through lucigenin chemiluminescence assays. RESULTS The selected compounds assisted the fluorescently labeled dye DiBAC4(3) to bind to the lipid rich intra-cellular entities, and thus produced a sharp green fluorescence by easily penetrating into the compound-induced depolarized membrane of MDR E. coli. These compounds have also triggered a significant generation of ROS from bacterial cells as compared to the conventional antibiotics. The current study demonstrated that harmaline (1), and its derivatives 2 and 3 were identified as anti-MDR agents against MDR strains of E. coli. Antibacterial effect of compounds 1-3 on MDR E. coli is possibly due to membrane depolarization due to ROS-induced damage to the bacterial cell membrane. CONCLUSION Harmaline and its derivatives were identified as anti-MDR agents against various highly resistant and Pakistani MDR clinical isolates of E. coli. These compounds may serve as the leads for further studies towards the development of treatment against the infections caused by MDR E. coli.
Collapse
Affiliation(s)
- Hina Siddiqui
- H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan
| | - Sehar Tasneem
- H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan
| | - Saba Farooq
- H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan
| | - Amtul Sami
- H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan
| | - Atta-Ur Rahman
- H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan
| | - Muhammad I Choudhary
- H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan
| |
Collapse
|
32
|
Bilbao JL, Iezzi R, Goldberg SN, Sami A, Akhan O, Giuliante F, Pompili M, Crocetti L, Malagari K, Valentini V, Gasbarrini A, Colosimo C, Manfredi R. The ten commandments of hepatic radioembolization: expert discussion and report from Mediterranean Interventional Oncology (MIOLive) congress 2017. Eur Rev Med Pharmacol Sci 2017; 21:4014-4021. [PMID: 29028102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Microsphere and particle technology represent the next-generation agents that have formed the basis of interventional oncology, an evolving subspecialty of interventional radiology. One of these platforms, yttrium-90 microspheres, is increasingly being used as a treatment modality for primary and secondary liver tumors. Due to the widespread use of radioembolization, a comprehensive review of the methodologic and technical considerations seems to be mandatory. This article summarizes the expert discussion and report from Mediterranean Interventional Oncology Live Congress (MIOLive 2017) that was held in Rome, Italy, integrating evidence-reported literature and experience-based perceptions, to assist not only residents and fellows who are training in interventional radiologists but also practicing colleagues who are approaching to this intra-arterial treatment.
Collapse
Affiliation(s)
- J L Bilbao
- Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Elimairi I, Alla A, Dyab F, Sami A, Baur D, Altay M, Quereshy F, Tozoglu S. A morphometric study of the hypoglossal and facial nerves for hypoglossal-facial nerve anastomosis. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.1133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
34
|
Elimairi I, Sami A, Suleiman A. Head and neck aspergillosis: multidisciplinary approach. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.1022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
35
|
Elimairi I, Elneil A, Khair B, Babker E, Hassan A, Sami A. Oculomotor nerve palsy treated by superior orbitotomy approach. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Elimairi I, Sami A, Elamin E, Elhassan L, Elimairi A, Elhassan A. The use of audit in the diagnosis of oral leishmaniasis. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.1157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Elimairi I, Sami A, Baur D, Elimairi A, Minisandram A. Effect of novalgin, ibuprofen and therapeutic jaw exercises on patients with facial arthromyalgia. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.1156] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
38
|
Elimairi I, Sami A, Elimairi A, Elnyal A, Musa B. Pain in parotid: reporting seventeen cases of first bite syndrome. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.1021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
Abdelrahim A, Elimairi A, Elimairi I, Sami A. Progressive bimaxillary osteolysis (Gorhams disease): clinicopathological presentation and treatment. Int J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.ijom.2015.08.683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Elimairi I, Sami A, Elimairi A. Radiosensitive undifferentiated like carcinoma (LEC) on the tongue. Int J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.ijom.2015.08.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
41
|
Elimairi I, Elias H, Sami A, Elimairi A. Orbital multilocular Hydatid cyst: a rare cause of eye proptosis. Int J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.ijom.2015.08.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
42
|
Elimairi I, Sami A, Elimairi A. Synchronous thymus, parathyroid, and osteosarcoma: malignant hamartoma or neoplasia syndrome? Int J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.ijom.2015.08.536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Ahmed S, Bathe O, Berry S, Buie D, Davies J, Doll C, Dowden S, Gill S, Gordon V, Hebbard P, Jones E, Kennecke H, Koski S, Krahn M, Le D, Lim H, Lund C, Luo Y, Mcffadden A, Mcghie J, Mulder K, Park J, Rashidi F, Sami A, Tan KT, Wong R. Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014. ACTA ACUST UNITED AC 2015; 22:e113-23. [PMID: 25908916 DOI: 10.3747/co.22.2362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The 16th annual Western Canadian Gastrointestinal Cancer Consensus Conference was held in Saskatoon, Saskatchewan, September 4-5, 2014. The Consensus Conference is an interactive, multidisciplinary event attended by health care professionals from across western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) involved in the care of gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; radiologists; and allied health care professionals participated in presentation and discussion sessions for the purposes of developing the recommendations presented here. This consensus statement addresses current issues in the management of colorectal cancer.
Collapse
Affiliation(s)
- S Ahmed
- Saskatchewan: Medical Oncology (Ahmed, Sami) and Radiation Oncology (Le), Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon; Pathology (Jones), University of Saskatchewan, Regina; Surgery (Luo), Diagnostic Radiology (Rashidi), and Interventional Radiology (Tan), University of Saskatchewan, Saskatoon
| | - O Bathe
- Alberta: Department of Surgery (Bathe, Buie), University of Calgary, Calgary; Radiation Oncology (Doll) and Medical Oncology (Dowden), Tom Baker Cancer Centre, University of Calgary, Calgary; Medical Oncology (Koski, Mulder), Cross Cancer Centre, University of Alberta, Edmonton
| | - S Berry
- Ontario: Medical Oncology (Berry), Sunnybrook Odette Cancer Centre, University of Toronto, Toronto
| | - D Buie
- Alberta: Department of Surgery (Bathe, Buie), University of Calgary, Calgary; Radiation Oncology (Doll) and Medical Oncology (Dowden), Tom Baker Cancer Centre, University of Calgary, Calgary; Medical Oncology (Koski, Mulder), Cross Cancer Centre, University of Alberta, Edmonton
| | - J Davies
- British Columbia: Medical Oncology (Davies), BC Cancer Agency-Centre for the Southern Interior, Kelowna; Medical Oncology (Gill, Kennecke, Lim, Mcghie), BC Cancer Agency, University of BC, Vancouver; Radiation Oncology (Lund), BC Cancer Agency-Fraser Valley Cancer Centre, Fraser Valley; Surgical Oncology (Mcffadden), BC Cancer Agency, Vancouver
| | - C Doll
- Alberta: Department of Surgery (Bathe, Buie), University of Calgary, Calgary; Radiation Oncology (Doll) and Medical Oncology (Dowden), Tom Baker Cancer Centre, University of Calgary, Calgary; Medical Oncology (Koski, Mulder), Cross Cancer Centre, University of Alberta, Edmonton
| | - S Dowden
- Alberta: Department of Surgery (Bathe, Buie), University of Calgary, Calgary; Radiation Oncology (Doll) and Medical Oncology (Dowden), Tom Baker Cancer Centre, University of Calgary, Calgary; Medical Oncology (Koski, Mulder), Cross Cancer Centre, University of Alberta, Edmonton
| | - S Gill
- British Columbia: Medical Oncology (Davies), BC Cancer Agency-Centre for the Southern Interior, Kelowna; Medical Oncology (Gill, Kennecke, Lim, Mcghie), BC Cancer Agency, University of BC, Vancouver; Radiation Oncology (Lund), BC Cancer Agency-Fraser Valley Cancer Centre, Fraser Valley; Surgical Oncology (Mcffadden), BC Cancer Agency, Vancouver
| | - V Gordon
- Manitoba: Medical Oncology (Gordon, Krahn, Wong), Cancer Care Manitoba, University of Manitoba, Winnipeg; Surgery (Hebbard, Park), University of Manitoba, Winnipeg
| | - P Hebbard
- Manitoba: Medical Oncology (Gordon, Krahn, Wong), Cancer Care Manitoba, University of Manitoba, Winnipeg; Surgery (Hebbard, Park), University of Manitoba, Winnipeg
| | - E Jones
- Saskatchewan: Medical Oncology (Ahmed, Sami) and Radiation Oncology (Le), Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon; Pathology (Jones), University of Saskatchewan, Regina; Surgery (Luo), Diagnostic Radiology (Rashidi), and Interventional Radiology (Tan), University of Saskatchewan, Saskatoon
| | - H Kennecke
- British Columbia: Medical Oncology (Davies), BC Cancer Agency-Centre for the Southern Interior, Kelowna; Medical Oncology (Gill, Kennecke, Lim, Mcghie), BC Cancer Agency, University of BC, Vancouver; Radiation Oncology (Lund), BC Cancer Agency-Fraser Valley Cancer Centre, Fraser Valley; Surgical Oncology (Mcffadden), BC Cancer Agency, Vancouver
| | - S Koski
- Alberta: Department of Surgery (Bathe, Buie), University of Calgary, Calgary; Radiation Oncology (Doll) and Medical Oncology (Dowden), Tom Baker Cancer Centre, University of Calgary, Calgary; Medical Oncology (Koski, Mulder), Cross Cancer Centre, University of Alberta, Edmonton
| | - M Krahn
- Manitoba: Medical Oncology (Gordon, Krahn, Wong), Cancer Care Manitoba, University of Manitoba, Winnipeg; Surgery (Hebbard, Park), University of Manitoba, Winnipeg
| | - D Le
- Saskatchewan: Medical Oncology (Ahmed, Sami) and Radiation Oncology (Le), Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon; Pathology (Jones), University of Saskatchewan, Regina; Surgery (Luo), Diagnostic Radiology (Rashidi), and Interventional Radiology (Tan), University of Saskatchewan, Saskatoon
| | - H Lim
- British Columbia: Medical Oncology (Davies), BC Cancer Agency-Centre for the Southern Interior, Kelowna; Medical Oncology (Gill, Kennecke, Lim, Mcghie), BC Cancer Agency, University of BC, Vancouver; Radiation Oncology (Lund), BC Cancer Agency-Fraser Valley Cancer Centre, Fraser Valley; Surgical Oncology (Mcffadden), BC Cancer Agency, Vancouver
| | - C Lund
- British Columbia: Medical Oncology (Davies), BC Cancer Agency-Centre for the Southern Interior, Kelowna; Medical Oncology (Gill, Kennecke, Lim, Mcghie), BC Cancer Agency, University of BC, Vancouver; Radiation Oncology (Lund), BC Cancer Agency-Fraser Valley Cancer Centre, Fraser Valley; Surgical Oncology (Mcffadden), BC Cancer Agency, Vancouver
| | - Y Luo
- Saskatchewan: Medical Oncology (Ahmed, Sami) and Radiation Oncology (Le), Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon; Pathology (Jones), University of Saskatchewan, Regina; Surgery (Luo), Diagnostic Radiology (Rashidi), and Interventional Radiology (Tan), University of Saskatchewan, Saskatoon
| | - A Mcffadden
- British Columbia: Medical Oncology (Davies), BC Cancer Agency-Centre for the Southern Interior, Kelowna; Medical Oncology (Gill, Kennecke, Lim, Mcghie), BC Cancer Agency, University of BC, Vancouver; Radiation Oncology (Lund), BC Cancer Agency-Fraser Valley Cancer Centre, Fraser Valley; Surgical Oncology (Mcffadden), BC Cancer Agency, Vancouver
| | - J Mcghie
- British Columbia: Medical Oncology (Davies), BC Cancer Agency-Centre for the Southern Interior, Kelowna; Medical Oncology (Gill, Kennecke, Lim, Mcghie), BC Cancer Agency, University of BC, Vancouver; Radiation Oncology (Lund), BC Cancer Agency-Fraser Valley Cancer Centre, Fraser Valley; Surgical Oncology (Mcffadden), BC Cancer Agency, Vancouver
| | - K Mulder
- Alberta: Department of Surgery (Bathe, Buie), University of Calgary, Calgary; Radiation Oncology (Doll) and Medical Oncology (Dowden), Tom Baker Cancer Centre, University of Calgary, Calgary; Medical Oncology (Koski, Mulder), Cross Cancer Centre, University of Alberta, Edmonton
| | - J Park
- Manitoba: Medical Oncology (Gordon, Krahn, Wong), Cancer Care Manitoba, University of Manitoba, Winnipeg; Surgery (Hebbard, Park), University of Manitoba, Winnipeg
| | - F Rashidi
- Saskatchewan: Medical Oncology (Ahmed, Sami) and Radiation Oncology (Le), Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon; Pathology (Jones), University of Saskatchewan, Regina; Surgery (Luo), Diagnostic Radiology (Rashidi), and Interventional Radiology (Tan), University of Saskatchewan, Saskatoon
| | - A Sami
- Saskatchewan: Medical Oncology (Ahmed, Sami) and Radiation Oncology (Le), Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon; Pathology (Jones), University of Saskatchewan, Regina; Surgery (Luo), Diagnostic Radiology (Rashidi), and Interventional Radiology (Tan), University of Saskatchewan, Saskatoon
| | - K T Tan
- Saskatchewan: Medical Oncology (Ahmed, Sami) and Radiation Oncology (Le), Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon; Pathology (Jones), University of Saskatchewan, Regina; Surgery (Luo), Diagnostic Radiology (Rashidi), and Interventional Radiology (Tan), University of Saskatchewan, Saskatoon
| | - R Wong
- Manitoba: Medical Oncology (Gordon, Krahn, Wong), Cancer Care Manitoba, University of Manitoba, Winnipeg; Surgery (Hebbard, Park), University of Manitoba, Winnipeg
| |
Collapse
|
44
|
Adel A, Abdullah A, Yazeed A, Juan A, Sami A, Juan Z. Differences in mortality between weekend and weekday hospital admissions among stroke patients in Florida. HAMDAN MEDICAL JOURNAL 2015. [DOI: 10.7707/hmj.584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
45
|
Elimairi I, Abdoun O, Sami A. OI0410 Accuracy of Lugol iodine in detection of oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol 2014. [DOI: 10.1016/j.oooo.2014.01.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
46
|
Elimairi I, Sami A. CR0412 Leishmaniasis with oral presentations: a new entity? Oral Surg Oral Med Oral Pathol Oral Radiol 2014. [DOI: 10.1016/j.oooo.2014.01.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
47
|
Sami A, Shakoori A. Potential of Azadirachtin and Neem (Azadirachta indica) Based Saponins as Biopesticides for In vitro Insect Pests Cellulase (Beta-1,4-Endoglucanase) Enzyme Inhibition and In vivo Repellency on Tribolium castaneum. ACTA ACUST UNITED AC 2014. [DOI: 10.9734/bbj/2014/6903] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
48
|
Merad M, Chachaty E, Gachot B, Alibay A, Dipalma M, Sami A. Epidemiology, Resistance Profile and Origin of Bacteremia in Non-Neutropenic Patients with Solid Tumor. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34103-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
49
|
Ahmed S, Lim J, Shahid R, Bhatt H, Roberts S, Ubhi C, Lee-Ying R, Sami A. 3525 POSTER Chemotherapy-Related Thrombocytosis and Its Association With Thromboembolism (TE). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71181-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
50
|
Sami A, Azizou H, Youklif I, Karkouri M, El azhari A. Tumeur fibreuse solitaire de l’orbite (un cas). African Journal of Neurological Sciences 2010. [DOI: 10.4314/ajns.v28i1.55155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|